Summary

The global multiomics market is estimated to reach USD 5.70 billion by 2031 from USD 3.18 billion in 2026, at a CAGR of 12.3% during the forecast period. The global multiomics market is expected to witness significant growth through 2031, driven by the increasing adoption of integrated genomic, transcriptomic, proteomic, metabolomic, and epigenomic profiling technologies. The market expansion is supported by rising demand for comprehensive biological characterization in oncology, drug discovery, precision medicine, and translational research. Advancements in single-cell analysis, spatial omics, next-generation sequencing, mass spectrometry, and AI-enabled bioinformatics platforms are further accelerating adoption. However, high technology costs, complex data integration requirements, and the need for specialized computational expertise may limit adoption across resource-constrained research environments. The product segment accounted for the largest share by offering in the multiomics market in 2025. Based on offering, the multiomics market is segmented into products and services. In 2025, products accounted for the largest share of the market, driven by widespread adoption of sequencing platforms, analytical instruments, assay kits, reagents, consumables, and software solutions required throughout multiomics workflows. These products support sample preparation, sequencing, characterization, and data analysis activities across pharmaceutical companies, biotechnology firms, academic institutions, and research laboratories. The services segment is expected to grow at the fastest rate during the forecast period, supported by increasing outsourcing of complex multiomics profiling, bioinformatics analysis, and integrated omics interpretation to specialized service providers. Single-cell omics accounted for the largest share, by method, in the multiomics market in 2025. Based on method, the multiomics market is segmented into epigenomics, single-cell omics, spatial omics, long-read & long-range sequencing, proteomics, and other methods. Single-cell omics accounted for the largest share in 2025 due to its ability to characterize cellular heterogeneity and molecular interactions at individual cell resolution. Increasing adoption in oncology, immunology, developmental biology, and drug discovery applications continues to support its leading position. Spatial omics is expected to register the fastest growth during the forecast period, driven by increasing demand for technologies that preserve tissue architecture while enabling simultaneous molecular profiling. The Asia Pacific is growing at the highest CAGR in the multiomics market from 2026 to 2031. The multiomics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, the Asia Pacific region is expected to register the highest CAGR, driven by increasing investments in genomics and life sciences research, expanding precision medicine initiatives, and the growing adoption of next-generation sequencing (NGS), single-cell, spatial biology, and high-resolution mass spectrometry technologies. Regional growth is further supported by rising government funding for omics research, rapid expansion of biotechnology and pharmaceutical R&D, increasing availability of advanced research infrastructure, and the growing presence of contract research organizations (CROs) and genomic service providers. Additionally, the strong presence of leading regional companies such as BGI Genomics and Novogene, along with continued investments by global multiomics technology providers, is strengthening the region's capabilities in multiomics research, biomarker discovery, and precision medicine applications, making Asia Pacific the fastest-growing market during the forecast period. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side - 70% and Demand Side - 30% • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30% • By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25% • By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East & Africa - 5% List of Companies Profiled in the Report • 10x Genomics, Inc. • Thermo Fisher Scientific Inc. • Illumina, Inc. • Oxford Nanopore Technologies plc • Bruker • PacBio • Danaher Corporation • Vizgen Corporation • Agilent Technologies, Inc • Biognosys AG • Merck KGaA • QIAGEN N.V. • Revvity, Inc. • Waters Corporation • Syngene International • Bio-Rad Laboratories, Inc • Takara Bio Inc • Metabolon, Inc • BGI Genomics Co., Ltd Research Coverage This research report categorizes the multiomics market by offering, method, technology, workflow, application, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the multiomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the multiomics market. This report covers competitive analysis of top players and upcoming startups in the multiomics market ecosystem. Key Benefits of Buying the Report The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall multiomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (rising adoption of multiomics in precision medicine and disease stratification, rapid adoption of single-cell and spatial multiomics, increasing accessibility of high-quality integrated omics data for research, and advances in AI, machine learning, and cloud bioinformatics for cross-omics data interpretation), restraints (complexity of multiomics data integration and standardization, and high costs associated with multiomics technologies limiting widespread adoption), opportunities (growing adoption of spatial proteomics for tissue-context analysis and biomarker discovery, and increasing emergence of single-cell proteomics for high-resolution cellular profiling), and challenges (lack of standardization across multiomics workflows) influencing the growth of multiomics market • Product Development/Innovation: Detailed insights on newly launched products of the multiomics market • Market Development: Comprehensive information about lucrative markets – the report analyses the Multiomics market across varied regions • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multiomics market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as 10x Genomics, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Oxford Nanopore Technologies plc (UK), and Bruker Corporation (US), among others

ページTOPに戻る

Table of Contents

1 INTRODUCTION 53
1.1 STUDY OBJECTIVES 53
1.2 MARKET DEFINITION 53
1.3 STUDY SCOPE 53
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 54
1.3.2 INCLUSIONS & EXCLUSIONS 55
1.3.3 YEARS CONSIDERED 56
1.3.4 CURRENCY CONSIDERED 57
1.4 STAKEHOLDERS 57
2 EXECUTIVE SUMMARY 58
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 58
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 60
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 61
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 62
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 63
3 PREMIUM INSIGHTS 64
3.1 MULTIOMICS MARKET OVERVIEW 64
3.2 MULTIOMICS MARKET, BY OFFERING AND REGION 65
3.3 MULTIOMICS MARKET: GEOGRAPHIC SNAPSHOT 66
3.4 MULTIOMICS MARKET, BY OFFERING 66
4 MARKET OVERVIEW 67
4.1 INTRODUCTION 67
4.2 MARKET DYNAMICS 67
4.2.1 DRIVERS 68
4.2.1.1 Rising use of multiomics in precision medicine and disease stratification 68
4.2.1.2 Rapid adoption of single-cell and spatial multiomics 69
4.2.1.3 Increasing accessibility of high-quality, integrated omics data for research 69
4.2.1.4 AI, machine learning, and cloud bioinformatics improving cross-omics interpretation 69
4.2.2 RESTRAINTS 70
4.2.2.1 Complexity of multiomics data integration and standardization 70
4.2.2.2 High costs constrain technology adoption 70
4.2.3 OPPORTUNITIES 70
4.2.3.1 Growing adoption of spatial proteomics for tissue-context analysis and biomarker discovery 70
4.2.3.2 Increasing emergence of single-cell proteomics for high-resolution characterization of cellular profiles 71
4.2.4 CHALLENGES 71
4.2.4.1 Lack of standardization across multiomics workflows 71
4.3 UNMET NEEDS AND WHITE SPACES 71
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 72
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 73
5 INDUSTRY TRENDS 75
5.1 PORTER’S FIVE FORCES ANALYSIS 75
5.1.1 THREAT OF NEW ENTRANTS 76
5.1.2 THREAT OF SUBSTITUTES 76
5.1.3 BARGAINING POWER OF BUYERS 76
5.1.4 BARGAINING POWER OF SUPPLIERS 77
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 77
5.2 MACROECONOMIC OUTLOOK 77
5.2.1 INTRODUCTION 77
5.2.2 GDP TRENDS AND FORECAST 77
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 78
5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY 78
5.3 VALUE CHAIN ANALYSIS 78
5.4 ECOSYSTEM ANALYSIS 80
5.5 PRICING ANALYSIS 81
5.5.1 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE (2023–2025) 82
5.5.2 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025 83
5.5.3 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 83
5.6 TRADE ANALYSIS 85
5.6.1 IMPORT DATA FOR HS CODE 9027 85
5.6.2 EXPORT DATA FOR HS CODE 9027 86
5.6.3 IMPORT VOLUME FOR HS CODE 9027 87
5.6.4 EXPORT VOLUME FOR HS CODE 9027 87
5.7 KEY CONFERENCES & EVENTS 88
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89
5.9 INVESTMENT/FUNDING ACTIVITY 90
5.10 CASE STUDY ANALYSIS 90
5.10.1 ADVANCED MULTIOMICS PROFILING TO SUPPORT PRECISION MEDICINE ADOPTION 91
5.10.2 INTEGRATED LONG-READ SEQUENCING TO SUPPORT MULTIOMICS RESEARCH 91
5.10.3 MULTIOMICS DATA INTEGRATION TO ACCELERATE BIOMARKER DISCOVERY 92
5.11 IMPACT OF 2025 US TARIFFS—MULTIOMICS MARKET 92
5.11.1 INTRODUCTION 92
5.11.2 KEY TARIFF RATES 93
5.11.3 PRICE IMPACT ANALYSIS 94
5.11.4 IMPACT ON COUNTRIES/REGIONS 94
5.11.4.1 North America 94
5.11.4.2 Europe 94
5.11.4.3 Asia Pacific 95
5.11.5 IMPACT ON END-USE INDUSTRIES 96
5.11.5.1 Pharmaceutical and biotechnology companies 96
5.11.5.2 Hospitals and diagnostic laboratories 96
5.11.5.3 Academic & research institutes 97
5.11.5.4 CROs & CDMOs 97
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 98
6.1 KEY TECHNOLOGIES 98
6.1.1 SINGLE-CELL MULTIOMICS CO-ASSAYS AND SCALABLE BARCODING 98
6.1.2 SPATIAL MULTIOMICS AND SUBCELLULAR TISSUE MAPPING 98
6.1.3 HIGH-PLEX PROTEOGENOMICS AND NGS/PCR-BASED PROTEIN READOUTS 99
6.2 ADJACENT TECHNOLOGIES 99
6.2.1 MICROARRAYS AND HYBRIDIZATION-BASED PROFILING 99
6.2.2 DIGITAL PATHOLOGY AND ADVANCED SPATIAL IMAGING 99
6.3 COMPLEMENTARY TECHNOLOGIES 100
6.3.1 MICROFLUIDICS, CELL/NUCLEI CAPTURE, AND SAMPLE INDEXING 100
6.3.2 HIGH-RESOLUTION MASS SPECTROMETRY AND ION MOBILITY 100
6.4 TECHNOLOGY/PRODUCT ROADMAP 100
6.5 PATENT ANALYSIS 101
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025 101
6.6 FUTURE APPLICATIONS 102
6.7 IMPACT OF AI/GEN AI ON MULTIOMICS MARKET 103
6.7.1 TOP USE CASES AND MARKET POTENTIAL 104
6.7.2 BEST PRACTICES IN AI-ENABLED MULTIOMICS WORKFLOWS 104
6.7.3 CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET 105
6.7.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 105
6.7.5 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET 105
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 107
7.1 REGIONAL REGULATIONS AND COMPLIANCE 107
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
7.1.2 INDUSTRY STANDARDS 110
7.2 SUSTAINABILITY INITIATIVES 111
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 111
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 111
8 MULTIOMICS MARKET, BY OFFERING 113
8.1 INTRODUCTION 114
8.2 PRODUCTS 114
8.2.1 CONSUMABLES 117
8.2.1.1 Increasing experiment volumes, higher multiplexing, and recurring reagent requirements support growth 117
8.2.1.2 Assay kits & reagents 120
8.2.1.2.1 Recurring assay consumption, higher multiplexing, and improved low-input performance drive market growth 120
8.2.1.3 Other consumables 122
8.2.2 INSTRUMENTS & SOFTWARE 125
8.2.2.1 Integrated multiomics platforms, automated workflows, and AI-enabled data interpretation strengthen demand 125
8.3 SERVICES 128
8.3.1 RISING OUTSOURCING OF SPECIALIZED PROFILING AND INTERPRETATION TO DRIVE MARKET GROWTH 128
9 MULTIOMICS MARKET, BY TECHNOLOGY 132
9.1 INTRODUCTION 133
9.2 SEQUENCING 133
9.2.1 LONG-READ SEQUENCING 136
9.2.1.1 Nanopore sequencing 139
9.2.1.1.1 Real-time native-molecule analysis, scalable platforms, and integrated genomic–epigenomic readouts are accelerating nanopore sequencing adoption 139
9.2.1.2 SMRT Sequencing 142
9.2.1.2.1 High-accuracy HiFi reads and lower sequencing cost to expand SMRT-based multiomics 142
9.2.2 OTHER SEQUENCING TECHNOLOGIES 145
9.3 PROTEOMICS 148
9.3.1 ADVANCES IN HIGH-SENSITIVITY MASS SPECTROMETRY, SINGLE-CELL ANALYSIS, AND SCALABLE PROTEIN QUANTIFICATION ARE ACCELERATING PROTEOMICS ADOPTION IN MULTIOMICS RESEARCH 148
9.4 OTHER TECHNOLOGIES 151
10 MULTIOMICS MARKET, BY METHOD 154
10.1 INTRODUCTION 155
10.2 SINGLE-CELL OMICS 155
10.2.1 IMPROVED CELL CAPTURE AND GROWING DEMAND TO RESOLVE CELLULAR HETEROGENEITY DRIVE MARKET GROWTH 155
10.2.2 SINGLE-CELL TRANSCRIPTOMICS 158
10.2.2.1 Higher sample throughput, improved cell recovery, and compatibility with fixed clinical samples are expanding single-cell transcriptomics 158
10.2.3 SINGLE-CELL EPIGENOMICS 161
10.2.3.1 Growing interest in gene regulation, chromatin state, and treatment resistance is accelerating single-cell epigenomics research 161
10.2.4 SINGLE-CELL PROTEOMICS 164
10.2.4.1 Ultrasensitive mass spectrometry and higher-throughput protein quantification expanding functional analysis at single-cell resolution 164
10.2.5 SINGLE-CELL GENOMICS 167
10.2.5.1 Improved detection of clonal variation and simultaneous genotype-phenotype analysis are driving single-cell genomics adoption 167
10.2.6 OTHER SINGLE-CELL OMICS 169
10.3 PROTEOMICS 172
10.3.1 MS-BASED PROTEOMICS 175
10.3.1.1 Data-independent acquisition and improved quantitative depth to sustain MS-based proteomics leadership 175
10.3.2 NGS-BASED PROTEOMICS 178
10.3.2.1 Sequencing readouts and ultra-high-plex panels to make NGS-based proteomics the fastest-growing proteomics method 178
10.3.3 PCR-BASED PROTEOMICS 180
10.3.3.1 Sensitive proximity-amplification assays to support targeted, low-volume protein profiling 180
10.3.4 OTHER PROTEOMICS METHODS 183
10.4 SPATIAL OMICS 186
10.4.1 SPATIAL TRANSCRIPTOMICS 189
10.4.1.1 Whole-transcriptome tissue mapping and higher resolution to sustain spatial transcriptomics leadership 189
10.4.2 SPATIAL PROTEOMICS 192
10.4.2.1 Higher-plex imaging and tissue phenotyping to accelerate spatial proteomics adoption 192
10.4.3 SPATIAL EPIGENOMICS 194
10.4.3.1 Mapping regulatory states within tissue to expand spatial epigenomics from early research applications 194
10.4.4 SPATIAL GENOMICS 197
10.4.4.1 In situ variant and copy-number mapping to support spatial genomics growth 197
10.4.5 OTHER SPATIAL OMICS 199
10.5 LONG-READ & LONG-RANGE SEQUENCING 202
10.5.1 IMPROVED STRUCTURAL VARIANT, ISOFORM, AND NATIVE EPIGENETIC RESOLUTION TO ACCELERATE ADOPTION 202
10.5.2 LONG-READ SEQUENCING 205
10.5.2.1 Higher accuracy and throughput to ensure market leadership 205
10.5.3 LONG-RANGE SEQUENCING 208
10.5.3.1 Genome mapping and linked information to improve structural and haplotype characterization 208
10.5.4 OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS 210
10.6 EPIGENOMICS 213
10.6.1 SEQUENCING-BASED EPIGENOMICS 216
10.6.1.1 DNA methylation sequencing 219
10.6.1.1.1 Genome-wide and targeted methylation analysis to sustain the largest sequencing-based epigenomics share 219
10.6.1.2 Chromatin accessibility sequencing 222
10.6.1.2.1 ATAC-seq adoption and regulatory element mapping to make accessibility profiling the fastest-growing epigenomics method 222
10.6.1.3 Histone modification profiling 225
10.6.1.3.1 Lower-input chromatin profiling to broaden analysis of histone-associated regulatory states 225
10.6.1.4 Chromatin interaction analysis 228
10.6.1.4.1 3D genome mapping to connect distal regulatory elements with gene activity 228
10.6.2 OTHER EPIGENOMICS METHODS 231
10.7 OTHER METHODS 234
11 MULTIOMICS MARKET, BY WORKFLOW 237
11.1 INTRODUCTION 238
11.2 SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION 238
11.2.1 HIGHER-THROUGHPUT MOLECULAR PROFILING AND INCREASINGLY SENSITIVE ANALYTICAL PLATFORMS TO STRENGTHEN SEQUENCING AND SAMPLE CHARACTERIZATION WORKFLOWS 238
11.3 SAMPLE PREPARATION 241
11.3.1 IMPROVED SAMPLE PRESERVATION, CELL CAPTURE, AUTOMATION, AND MULTIPLEXING TO EXPAND SCALE AND REPRODUCIBILITY OF MULTIOMICS STUDIES 241
11.4 DATA VISUALIZATION & ANALYSIS 244
11.4.1 AI-ENABLED ANALYTICS AND MULTIMODAL INTEGRATION TO ACCELERATE CONVERSION OF COMPLEX MULTIOMICS DATA INTO BIOLOGICAL INSIGHTS 244
12 MULTIOMICS MARKET, BY APPLICATION 248
12.1 INTRODUCTION 249
12.2 ONCOLOGY 249
12.2.1 GROWING USE OF TUMOR MULTIOMICS FOR BIOMARKER DISCOVERY AND PATIENT STRATIFICATION DRIVES MARKET LEADERSHIP 249
12.3 DRUG DISCOVERY & DEVELOPMENT 252
12.3.1 DATA-DRIVEN TARGET SELECTION AND MECHANISM STUDIES TO MAKE DRUG DISCOVERY FASTEST-GROWING APPLICATION 252
12.4 IMMUNOLOGY 255
12.4.1 LARGE-SCALE IMMUNE PROFILING PROGRAMS TO ACCELERATE MULTIMODAL IMMUNOLOGY RESEARCH 255
12.5 PRECISION MEDICINE 257
12.5.1 INTEGRATED MOLECULAR AND CLINICAL DATA TO EXPAND PATIENT-SPECIFIC DECISION SUPPORT 257
12.6 BIOMARKER DISCOVERY 260
12.6.1 CROSS-OMICS VALIDATION TO IMPROVE BIOMARKER ROBUSTNESS AND CLINICAL RELEVANCE 260
12.7 CELL BIOLOGY 263
12.7.1 HIGHER-RESOLUTION PROFILING OF CELL STATES, INTERACTIONS, AND DIFFERENTIATION PROCESSES EXPANDING ROLE OF MULTIOMICS IN CELL BIOLOGY 263
12.8 TRANSLATIONAL RESEARCH 266
12.8.1 IMPROVED ANALYSIS OF SPECIMENS AND MORE SCALABLE SPATIAL WORKFLOWS ACCELERATE TRANSLATION OF MULTIOMICS DISCOVERIES INTO THERAPEUTIC RESEARCH 266
12.9 NEUROLOGY 269
12.9.1 BRAIN-CELL ATLASES AND SPATIALLY RESOLVED MOLECULAR PROFILING DRIVE UNDERSTANDING OF NEUROLOGICAL DISEASE PROGRESSION AND THERAPEUTIC TARGETS 269
12.10 CLINICAL DIAGNOSTICS 271
12.10.1 GROWING CLINICAL SEQUENCING INFRASTRUCTURE TO SUPPORT MULTIOMICS-RELATED DIAGNOSTIC ADOPTION 271
12.11 OTHER APPLICATIONS 274
13 MULTIOMICS MARKET, BY END USER 277
13.1 INTRODUCTION 278
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 278
13.2.1 EXPANDING PRECISION MEDICINE INITIATIVES ACCELERATE MULTIOMICS ADOPTION 278
13.3 ACADEMIC & RESEARCH INSTITUTES 281
13.3.1 GROWING RESEARCH FUNDING DRIVING MULTIOMICS USAGE AMONG ACADEMIC AND RESEARCH INSTITUTES 281
13.4 CROS & CDMOS 284
13.4.1 OUTSOURCING OF COMPLEX PROFILING AND ANALYTICS TO MAKE CROS & CDMOS THE FASTEST-GROWING END USERS 284
13.5 HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES 287
13.5.1 CLINICAL EVIDENCE AND WORKFLOW STANDARDIZATION TO SUPPORT MEASURED ADOPTION IN HOSPITALS AND LABORATORIES 287
14 MULTIOMICS MARKET, BY REGION 290
14.1 INTRODUCTION 291
14.2 NORTH AMERICA 291
14.2.1 US 298
14.2.1.1 Regulatory acceptance, clinically integrated molecular testing, and population-scale health datasets accelerate multiomics adoption 298
14.2.2 CANADA 304
14.2.2.1 Population-scale precision health initiatives expand integration capacity 304
14.3 EUROPE 310
14.3.1 GERMANY 316
14.3.1.1 Clinical integration of genome sequencing and strong translational research networks drive market growth 316
14.3.2 UK 322
14.3.2.1 Population-scale multimodal datasets, NHS integration, and industry-backed biomarker programs propel market growth 322
14.3.3 FRANCE 327
14.3.3.1 Standardized precision-medicine pathways and strong oncology research networks drive market 327
14.3.4 ITALY 333
14.3.4.1 Shared research infrastructure widening access beyond leading academic centers 333
14.3.5 SPAIN 338
14.3.5.1 Hospital-linked genomics programs support steady adoption of integrated profiling 338
14.3.6 REST OF EUROPE 344
14.4 ASIA PACIFIC 350
14.4.1 CHINA 357
14.4.1.1 Large-scale genomic initiatives and rapid adoption of precision medicine technologies drive growth 357
14.4.2 JAPAN 363
14.4.2.1 Mature biobanks and pharmaceutical research support stable, high-value adoption 363
14.4.3 SOUTH KOREA 368
14.4.3.1 National bio-data infrastructure and digital-health capabilities accelerate multiomics use 368
14.4.4 INDIA 374
14.4.4.1 GenomeIndia and expanding translational capacity propel rapid growth in Indian multiomics market 374
14.4.5 AUSTRALIA 380
14.4.5.1 Mission-led genomics investment strengthens clinical translation and data integration 380
14.4.6 REST OF ASIA PACIFIC 386
14.5 LATIN AMERICA 392
14.5.1 BRAZIL 398
14.5.1.1 Growing genomics infrastructure and increasing precision medicine adoption drive market growth 398
14.5.2 REST OF LATIN AMERICA 403
14.6 MIDDLE EAST 409
14.6.1 GCC COUNTRIES 415
14.6.1.1 Saudi Arabia 421
14.6.1.1.1 Rising healthcare expenditure, expanding genomics research, and investments in precision medicine to propel market 421
14.6.1.2 UAE 427
14.6.1.2.1 Large-scale citizen sequencing moves genomics toward preventive and personalized care 427
14.6.1.3 Rest of GCC Countries 433
14.6.2 REST OF MIDDLE EAST 439
14.7 AFRICA 445
14.7.1 DESPITE EMERGING OPPORTUNITIES, GROWTH REMAINS SLOW DUE TO LIMITED ACCESS TO ADVANCED TECHNOLOGY AND INADEQUATE FUNDING & WORKFORCE 445
15 COMPETITIVE LANDSCAPE 451
15.1 OVERVIEW 451
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 451
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MULTIOMICS MARKET 451
15.3 REVENUE ANALYSIS, 2021–2025 452
15.4 MARKET SHARE ANALYSIS, 2025 453
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 456
15.5.1 STARS 456
15.5.2 EMERGING LEADERS 456
15.5.3 PERVASIVE PLAYERS 456
15.5.4 PARTICIPANTS 456
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 458
15.5.5.1 Company footprint 458
15.5.5.2 Region footprint 459
15.5.5.3 Offering footprint 459
15.5.5.4 Technology footprint 460
15.5.5.5 Workflow footprint 461
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 462
15.6.1 PROGRESSIVE COMPANIES 462
15.6.2 RESPONSIVE COMPANIES 462
15.6.3 DYNAMIC COMPANIES 462
15.6.4 STARTING BLOCKS 462
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 464
15.6.5.1 Detailed list of key startups/SMEs 464
15.6.5.2 Competitive benchmarking of key startups/SMEs 465
15.7 COMPANY VALUATION AND FINANCIAL METRICS 466
15.7.1 COMPANY VALUATION 466
15.7.2 FINANCIAL METRICS 466
15.8 BRAND/PRODUCT COMPARISON 467
15.9 COMPETITIVE SCENARIO 468
15.9.1 PRODUCT & SERVICE LAUNCHES 468
15.9.2 DEALS 468
15.9.3 EXPANSIONS 469
16 COMPANY PROFILES 470
16.1 KEY COMPANIES 470
16.1.1 10X GENOMICS 470
16.1.1.1 Business overview 470
16.1.1.2 Products & services offered 471
16.1.1.3 Recent developments 473
16.1.1.3.1 Product & service launches 473
16.1.1.3.2 Deals 473
16.1.1.4 MnM view 473
16.1.1.4.1 Key strengths 473
16.1.1.4.2 Strategic choices 474
16.1.1.4.3 Weaknesses and competitive threats 474
16.1.2 THERMO FISHER SCIENTIFIC INC. 475
16.1.2.1 Business overview 475
16.1.2.2 Products & services offered 476
16.1.2.3 Recent developments 478
16.1.2.3.1 Product & service launches 478
16.1.2.3.2 Deals 479
16.1.2.4 MnM view 480
16.1.2.4.1 Key strengths 480
16.1.2.4.2 Strategic choices 480
16.1.2.4.3 Weaknesses and competitive threats 480
16.1.3 ILLUMINA, INC. 481
16.1.3.1 Business overview 481
16.1.3.2 Products & services offered 482
16.1.3.3 Recent developments 484
16.1.3.3.1 Product & service launches 484
16.1.3.3.2 Deals 484
16.1.3.4 MnM view 485
16.1.3.4.1 Key strengths 485
16.1.3.4.2 Strategic choices 485
16.1.3.4.3 Weaknesses and competitive threats 485
16.1.4 OXFORD NANOPORE TECHNOLOGIES PLC 486
16.1.4.1 Business overview 486
16.1.4.2 Products & services offered 487
16.1.4.3 Recent developments 488
16.1.4.3.1 Deals 488
16.1.4.3.2 Expansions 489
16.1.4.4 MnM view 489
16.1.4.4.1 Key strengths 489
16.1.4.4.2 Strategic choices 490
16.1.4.4.3 Weaknesses and competitive threats 490
16.1.5 BRUKER 491
16.1.5.1 Business overview 491
16.1.5.2 Products & services offered 492
16.1.5.3 Recent developments 494
16.1.5.3.1 Product & service launches 494
16.1.5.3.2 Deals 495
16.1.5.4 MnM view 495
16.1.5.4.1 Key strengths 495
16.1.5.4.2 Strategic choices 495
16.1.5.4.3 Weaknesses and competitive threats 495
16.1.6 PACBIO 496
16.1.6.1 Business overview 496
16.1.6.2 Products & services offered 497
16.1.6.3 Recent developments 499
16.1.6.3.1 Product & service launches 499
16.1.6.3.2 Deals 499
16.1.7 DANAHER CORPORATION 501
16.1.7.1 Business overview 501
16.1.7.2 Products & services offered 502
16.1.7.3 Recent developments 504
16.1.7.3.1 Product & service launches 504
16.1.7.3.2 Deals 505
16.1.8 VIZGEN, INC. 506
16.1.8.1 Business overview 506
16.1.8.2 Products & services offered 506
16.1.8.3 Recent developments 508
16.1.8.3.1 Deals 508
16.1.9 AGILENT TECHNOLOGIES, INC. 509
16.1.9.1 Business overview 509
16.1.9.2 Products & services offered 510
16.1.9.3 Recent developments 513
16.1.9.3.1 Product & service launches 513
16.1.9.3.2 Deals 513
16.1.9.3.3 Expansions 514
16.1.10 BIOGNOSYS 515
16.1.10.1 Business overview 515
16.1.10.2 Products & services offered 515
16.1.10.3 Recent developments 516
16.1.10.3.1 Deals 516
16.1.11 MERCK KGAA 517
16.1.11.1 Business overview 517
16.1.11.2 Products & services offered 518
16.1.11.3 Recent developments 520
16.1.11.3.1 Expansions 520
16.1.12 QIAGEN N.V. 521
16.1.12.1 Business overview 521
16.1.12.2 Products & services offered 522
16.1.12.3 Recent developments 523
16.1.12.3.1 Product & service launches 523
16.1.12.3.2 Deals 524
16.1.12.3.3 Expansions 524
16.1.13 REVVITY, INC. 525
16.1.13.1 Business overview 525
16.1.13.2 Products & services offered 526
16.1.13.3 Recent developments 528
16.1.13.3.1 Product & service launches 528
16.1.13.3.2 Deals 528
16.1.14 WATERS CORPORATION 530
16.1.14.1 Business overview 530
16.1.14.2 Products & services offered 531
16.1.14.3 Recent developments 532
16.1.14.3.1 Product & service launches 532
16.1.14.3.2 Deals 533
16.1.14.3.3 Expansions 534
16.1.15 BIO-RAD LABORATORIES, INC. 535
16.1.15.1 Business overview 535
16.1.15.2 Products & services offered 536
16.1.15.3 Recent developments 537
16.1.15.3.1 Product & service launches 537
16.1.15.3.2 Deals 538
16.1.16 TAKARA BIO INC. 539
16.1.16.1 Business overview 539
16.1.16.2 Products & services offered 540
16.1.16.3 Recent developments 542
16.1.16.3.1 Expansions 542
16.1.17 METABOLON, INC. 543
16.1.17.1 Business overview 543
16.1.17.2 Products & services offered 543
16.1.17.3 Recent developments 544
16.1.17.3.1 Product & service launches 544
16.2 OTHER PLAYERS 545
16.2.1 BGI GENOMICS CO., LTD. 545
16.2.2 NOVOGENE CO., LTD. 546
16.2.3 AZENTA, INC. 548
16.2.4 EVOTEC SE 549
16.2.5 MEDGENOME LABS LTD. 550
16.2.6 CD GENOMICS 551
16.2.7 BIOGENITY 552
16.2.8 SAPIENT BIOANALYTICS, LLC 553
16.2.9 RAYBIOTECH, INC. 554
16.2.10 SOURCE BIOSCIENCE LTD. 555
17 RESEARCH METHODOLOGY 556
17.1 RESEARCH DATA 556
17.1.1 SECONDARY DATA 557
17.1.2 PRIMARY DATA 557
17.2 MARKET ESTIMATION METHODOLOGY 559
17.2.1 MARKET SIZE ESTIMATION 559
17.2.2 INSIGHTS OF PRIMARY EXPERTS 562
17.2.3 TOP-DOWN APPROACH 562
17.3 MARKET GROWTH RATE PROJECTIONS 563
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 565
17.5 RESEARCH ASSUMPTIONS 566
17.6 RESEARCH LIMITATIONS 566
17.7 RISK ANALYSIS 567
18 APPENDIX 568
18.1 DISCUSSION GUIDE 568
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 573
18.3 CUSTOMIZATION OPTIONS 574
18.4 RELATED REPORTS 575
18.5 AUTHOR DETAILS 576

ページTOPに戻る

List of Tables/Graphs

TABLE 1 MULTIOMICS MARKET: IMPACT ANALYSIS 68.
TABLE 2 MULTIOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS 76.
TABLE 3 MULTIOMICS MARKET: ROLE IN ECOSYSTEM 81.
TABLE 4 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD) 82.
TABLE 5 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025 (USD) 83.
TABLE 6 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2023–2025 (USD) 83.
TABLE 7 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION, 2023–2025 (USD) 84.
TABLE 8 IMPORT DATA FOR HS CODE 9027, 2021–2025, (USD THOUSAND) 85.
TABLE 9 EXPORT DATA HS CODE 9027, 2021–2025 (USD THOUSAND) 86.
TABLE 10 IMPORT VOLUME HS CODE 9027, 2021–2025 (TONS) 87.
TABLE 11 EXPORT VOLUME HS CODE 9027, 2021–2025 (TONS) 87.
TABLE 12 MULTIOMICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 88.
TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES 93.
TABLE 14 INDICATIVE LIST OF PATENTS IN MULTIOMICS MARKET, 2025–2026 102.
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET 105.
TABLE 16 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET 106.
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107.
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108.
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108.
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109.
TABLE 21 MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 114.
TABLE 22 MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 114.
TABLE 23 MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 115.
TABLE 24 NORTH AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115.
TABLE 25 EUROPE: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115.
TABLE 26 ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116.
TABLE 27 LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116.
TABLE 28 MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 116.
TABLE 29 GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117.
TABLE 30 MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 117.
TABLE 31 MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 118.
TABLE 32 NORTH AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 33 EUROPE: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 34 ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 35 LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 36 MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 119.
TABLE 37 GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120.
TABLE 38 ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 120.
TABLE 39 NORTH AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 40 EUROPE: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 41 ASIA PACIFIC: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 42 LATIN AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122.
TABLE 43 MIDDLE EAST: ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 122.
TABLE 44 GCC COUNTRIES: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122.
TABLE 45 OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 123.
TABLE 46 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 123.
TABLE 47 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 123.
TABLE 48 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 49 LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 50 MIDDLE EAST: OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 124.
TABLE 51 GCC COUNTRIES: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125.
TABLE 52 MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION) 126.
TABLE 53 NORTH AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126.
TABLE 54 EUROPE: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126.
TABLE 55 ASIA PACIFIC: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 56 LATIN AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 57 MIDDLE EAST: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION) 127.
TABLE 58 GCC COUNTRIES: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 128.
TABLE 59 MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 129.
TABLE 60 NORTH AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 61 EUROPE: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 62 ASIA PACIFIC: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130.
TABLE 63 LATIN AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130.
TABLE 64 MIDDLE EAST: MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 130.
TABLE 65 GCC COUNTRIES: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131.
TABLE 66 MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 133.
TABLE 67 SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 134.
TABLE 68 SEQUENCING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 134.
TABLE 69 NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134.
TABLE 70 EUROPE: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 71 ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 72 LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 73 MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 136.
TABLE 74 GCC COUNTRIES: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136.
TABLE 75 LONG-READ SEQUENCING TECHNOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 137.
TABLE 76 LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 137.
TABLE 77 NORTH AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 78 EUROPE: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 79 ASIA PACIFIC: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 80 LATIN AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 81 MIDDLE EAST: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 82 GCC COUNTRIES: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139.
TABLE 83 NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 140.
TABLE 84 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 85 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 86 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141.
TABLE 87 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141.
TABLE 88 MIDDLE EAST: NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 141.
TABLE 89 GCC COUNTRIES: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 90 SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 143.
TABLE 91 NORTH AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143.
TABLE 92 EUROPE: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143.
TABLE 93 ASIA PACIFIC: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 94 LATIN AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 95 MIDDLE EAST: SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 144.
TABLE 96 GCC COUNTRIES: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 97 OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 145.
TABLE 98 NORTH AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 99 EUROPE: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 100 ASIA PACIFIC: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 101 LATIN AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 102 MIDDLE EAST: OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 147.
TABLE 103 GCC COUNTRIES: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 104 PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 149.
TABLE 105 NORTH AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 106 EUROPE: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 107 ASIA PACIFIC: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 108 LATIN AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 109 MIDDLE EAST: PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 150.
TABLE 110 GCC COUNTRIES: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151.
TABLE 111 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 151.
TABLE 112 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 113 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 114 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 115 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 116 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 153.
TABLE 117 GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 118 MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 155.
TABLE 119 SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 156.
TABLE 120 SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 156.
TABLE 121 NORTH AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 122 EUROPE: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 123 ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 124 LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 125 MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 158.
TABLE 126 GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158.
TABLE 127 SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 159.
TABLE 128 NORTH AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159.
TABLE 129 EUROPE: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159.
TABLE 130 ASIA PACIFIC: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 131 LATIN AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 132 MIDDLE EAST: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 160.
TABLE 133 GCC COUNTRIES: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161.
TABLE 134 SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 161.
TABLE 135 NORTH AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 136 EUROPE: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 137 ASIA PACIFIC: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 138 LATIN AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 139 MIDDLE EAST: SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 163.
TABLE 140 GCC COUNTRIES: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164.
TABLE 141 SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 164.
TABLE 142 NORTH AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165.
TABLE 143 EUROPE: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165.
TABLE 144 ASIA PACIFIC: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165.
TABLE 145 LATIN AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 146 MIDDLE EAST: SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 166.
TABLE 147 GCC COUNTRIES: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 148 SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 167.
TABLE 149 NORTH AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 150 EUROPE: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 151 ASIA PACIFIC: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 152 LATIN AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 153 MIDDLE EAST: SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 169.
TABLE 154 GCC COUNTRIES: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 169.
TABLE 155 OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 170.
TABLE 156 NORTH AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 157 EUROPE: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 158 ASIA PACIFIC: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 159 LATIN AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 160 MIDDLE EAST: OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 171.
TABLE 161 GCC COUNTRIES: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172.
TABLE 162 PROTEOMICS METHOD MARKET, BY TYPE, 2024–2031 (USD MILLION) 172.
TABLE 163 PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 173.
TABLE 164 NORTH AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 165 EUROPE: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 166 ASIA PACIFIC: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 167 LATIN AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 168 MIDDLE EAST: PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 174.
TABLE 169 GCC COUNTRIES: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 170 MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 175.
TABLE 171 NORTH AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 172 EUROPE: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 173 ASIA PACIFIC: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 174 LATIN AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 175 MIDDLE EAST: MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 177.
TABLE 176 GCC COUNTRIES: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 177 NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 178.
TABLE 178 NORTH AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 179 EUROPE: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 180 ASIA PACIFIC: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 181 LATIN AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 182 MIDDLE EAST: NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 180.
TABLE 183 GCC COUNTRIES: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 184 PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 181.
TABLE 185 NORTH AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181.
TABLE 186 EUROPE: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181.
TABLE 187 ASIA PACIFIC: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 188 LATIN AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 189 MIDDLE EAST: PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 182.
TABLE 190 GCC COUNTRIES: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 191 OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 183.
TABLE 192 NORTH AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 193 EUROPE: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 194 ASIA PACIFIC: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 195 LATIN AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 196 MIDDLE EAST: OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 185.
TABLE 197 GCC COUNTRIES: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 198 SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 186.
TABLE 199 SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 187.
TABLE 200 NORTH AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 201 EUROPE: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 202 ASIA PACIFIC: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 203 LATIN AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 204 MIDDLE EAST: SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 188.
TABLE 205 GCC COUNTRIES: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 206 SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 189.
TABLE 207 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 208 EUROPE: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 209 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 210 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 211 MIDDLE EAST: SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 191.
TABLE 212 GCC COUNTRIES: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 213 SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 192.
TABLE 214 NORTH AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 215 EUROPE: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 216 ASIA PACIFIC: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 217 LATIN AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 218 MIDDLE EAST: SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 194.
TABLE 219 GCC COUNTRIES: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 194.
TABLE 220 SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 195.
TABLE 221 NORTH AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 222 EUROPE: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 223 ASIA PACIFIC: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 224 LATIN AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 225 MIDDLE EAST: SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 196.
TABLE 226 GCC COUNTRIES: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 227 SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 197.
TABLE 228 NORTH AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198.
TABLE 229 EUROPE: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198.
TABLE 230 ASIA PACIFIC: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198.
TABLE 231 LATIN AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 232 MIDDLE EAST: SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 199.
TABLE 233 GCC COUNTRIES: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 234 OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 200.
TABLE 235 NORTH AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 236 EUROPE: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 237 ASIA PACIFIC: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201.
TABLE 238 LATIN AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201.
TABLE 239 MIDDLE EAST: OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 201.
TABLE 240 GCC COUNTRIES: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 202.
TABLE 241 LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 202.
TABLE 242 LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 203.
TABLE 243 NORTH AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 244 EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 245 ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204.
TABLE 246 LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204.
TABLE 247 MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 204.
TABLE 248 GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 249 LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 205.
TABLE 250 NORTH AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 251 EUROPE: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 252 ASIA PACIFIC: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 253 LATIN AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 254 MIDDLE EAST: LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 207.
TABLE 255 GCC COUNTRIES: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 256 LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 208.
TABLE 257 NORTH AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 208.
TABLE 258 EUROPE: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 259 ASIA PACIFIC: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 260 LATIN AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 261 MIDDLE EAST: LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 210.
TABLE 262 GCC COUNTRIES: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 263 OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 211.
TABLE 264 NORTH AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211.
TABLE 265 EUROPE: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211.
TABLE 266 ASIA PACIFIC: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 267 LATIN AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 268 MIDDLE EAST: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 212.
TABLE 269 GCC COUNTRIES: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213.
TABLE 270 EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 213.
TABLE 271 EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 214.
TABLE 272 NORTH AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214.
TABLE 273 EUROPE: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214.
TABLE 274 ASIA PACIFIC: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 275 LATIN AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 276 MIDDLE EAST: EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 215.
TABLE 277 GCC COUNTRIES: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 278 SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 216.
TABLE 279 SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 217.
TABLE 280 NORTH AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 281 EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 282 ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218.
TABLE 283 LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218.
TABLE 284 MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 218.
TABLE 285 GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 219.
TABLE 286 DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 219.
TABLE 287 NORTH AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 288 EUROPE: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 289 ASIA PACIFIC: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221.
TABLE 290 LATIN AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221.
TABLE 291 MIDDLE EAST: DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 221.
TABLE 292 GCC COUNTRIES: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222.
TABLE 293 CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 222.
TABLE 294 NORTH AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223.
TABLE 295 EUROPE: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223.
TABLE 296 ASIA PACIFIC: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224.
TABLE 297 LATIN AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224.
TABLE 298 MIDDLE EAST: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 224.
TABLE 299 GCC COUNTRIES: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 225.
TABLE 300 HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 225.
TABLE 301 NORTH AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226.
TABLE 302 EUROPE: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226.
TABLE 303 ASIA PACIFIC: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 227.
TABLE 304 LATIN AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 227.
TABLE 305 MIDDLE EAST: HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 227.
TABLE 306 GCC COUNTRIES: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 228.
TABLE 307 CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION) 228.
TABLE 308 NORTH AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 229.
TABLE 309 EUROPE: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 229.
TABLE 310 ASIA PACIFIC: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 230.
FIGURE 1 MARKETS COVERED AND REGIONS CONSIDERED 54.
FIGURE 2 MARKET SCENARIO 59.
FIGURE 3 GLOBAL MULTIOMICS MARKET, 2024–2031 59.
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIOMICS MARKET, 2023–2026 60.
FIGURE 5 DISRUPTIONS INFLUENCING THE GROWTH OF MULTIOMICS MARKET 61.
FIGURE 6 HIGH-GROWTH SEGMENTS IN MULTIOMICS MARKET, 2026–2031 62.
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN MULTIOMICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 63.
FIGURE 8 RAPID ADOPTION OF SINGLE-CELL AND SPATIAL MULTIOMICS TO DRIVE MARKET 64.
FIGURE 9 PRODUCTS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025 65.
FIGURE 10 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 66.
FIGURE 11 PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD 66.
FIGURE 12 MULTIOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67.
FIGURE 13 MULTIOMICS MARKET: PORTERS FIVE FORCES ANALYSIS 75.
FIGURE 14 MULTIOMICS MARKET: VALUE CHAIN ANALYSIS 79.
FIGURE 15 MULTIOMICS MARKET: ECOSYSTEM ANALYSIS 80.
FIGURE 16 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD) 82.
FIGURE 17 AVERAGE SELLING PRICE OF CONSUMABLES, 2023– 2025 (USD) 83.
FIGURE 18 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2025 (USD) 84.
FIGURE 19 AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 (USD) 85.
FIGURE 20 MULTIOMICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89.
FIGURE 21 INVESTMENT/FUNDING ACTIVITY IN MULTIOMICS MARKET 90.
FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025 101.
FIGURE 23 IMPACT OF AI/GEN AI ON MULTIOMICS MARKET 103.
FIGURE 24 NORTH AMERICA: MULTIOMICS MARKET SNAPSHOT 292.
FIGURE 25 ASIA PACIFIC: MULTIOMICS MARKET SNAPSHOT 350.
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION) 453.
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 454.
FIGURE 28 MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 457.
FIGURE 29 MULTIOMICS MARKET: COMPANY FOOTPRINT 458.
FIGURE 30 MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 463.
FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 466.
FIGURE 32 EV/EBITDA OF KEY VENDORS 466.
FIGURE 33 MULTIOMICS MARKET: BRAND/PRODUCT COMPARISON 467.
FIGURE 34 10X GENOMICS: COMPANY SNAPSHOT (2025) 471.
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 476.
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 482.
FIGURE 37 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025) 487.
FIGURE 38 BRUKER: COMPANY SNAPSHOT (2025) 492.
FIGURE 39 PACBIO.: COMPANY SNAPSHOT (2025) 497.
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 502.
FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 510.
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2025) 518.
FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2025) 521.
FIGURE 44 REVVITY: COMPANY SNAPSHOT (2025) 526.
FIGURE 45 WATERS CORPORATION: COMPANY SNAPSHOT (2025) 531.
FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 536.
FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT (2025) 540.
FIGURE 48 RESEARCH DESIGN 556.
FIGURE 49 MULTIOMICS MARKET: BREAKDOWN OF PRIMARIES 558.
FIGURE 50 MULTIOMICS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 559.
FIGURE 51 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 560.
FIGURE 52 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC. (2025) 560.
FIGURE 53 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 562.
FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 562.
FIGURE 55 MULTIOMICS MARKET CAGR PROJECTIONS 564.
FIGURE 56 DATA TRIANGULATION METHODOLOGY 565.